|
|
|
| Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis ? |
| Lan-Lan Xiao, Xiao-Xin Wu, Jia-Jia Chen, Dong Yan, Dong-Yan Shi, Jian-Rong Huang, Xiao-Wei Xu ∗, Lan-Juan Li |
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China
? Note: The abstract of this study was presented as a poster at the Asian Pacific Association for the Study of the Liver (APASL) 2020, which was held in Bali, Indonesia on March 4-8, 2020.
∗ Corresponding author.
E-mail address: xxw69@zju.edu.cn (X.-W. Xu). |
|
|
|
Abstract Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) has a high short-term mortality. However, the treatment progression for HBV-ACLF in China in the past decade has not been well characterized. The present study aimed to determine whether the HBV-ACLF treatment has significantly improved during the past decade.
Methods: This study retrospectively compared short-term (28/56 days) survival rates of two different nationwide cohorts (cohort I: 2008-2011 and cohort II: 2012-2015). Eligible HBV-ACLF patients were en- rolled retrospectively. Patients in the cohorts I and II were assigned either to the standard medical ther- apy (SMT) group (cohort I-SMT, cohort II-SMT) or artificial liver support system (ALSS) group (cohort I-ALSS, cohort II-ALSS). Propensity score matching analysis was conducted to eliminate baseline differences, and multivariate logistic regression analysis was used to explore the independent factors for 28-day survival.
Results: Short-term (28/56 days) survival rates were significantly higher in the ALSS group than those in the SMT group ( P < 0.05) and were higher in the cohort II than those in the cohort I ( P < 0.001). After propensity score matching, short-term (28/56 days) survival rates were higher in the cohort II than those in the cohort I for both SMT (60.7% vs. 53.0%, 50.0% vs. 39.8%, P < 0.05) and ALSS (66.1% vs. 56.5%, 53.0% vs. 44.4%, P < 0.05) treatments. The 28-day survival rate was higher in patients treated with nucleos(t)ide analogs than in patients without such treatments ( P = 0.046). Multivariate logistic regression analysis revealed that ALSS (OR = 0.962, 95% CI: 0.951-0.973, P = 0.038), nucleos(t)ide analogs (OR = 0.927, 95% CI: 0.871-0.983, P = 0.046), old age (OR = 1.028, 95% CI: 1.015-1.041, P < 0.001), total bilirubin (OR = 1.002, 95% CI: 1.001-1.003, P = 0.004), INR (OR = 1.569, 95% CI: 1.044-2.358, P < 0.001), COSSH-ACLF grade (OR = 2.683, 95% CI: 1.792-4.017, P < 0.001), and albumin (OR = 0.952, 95% CI: 0.924-0.982, P = 0.002) were independent factors for 28-day mortality.
Conclusions: The treatment for patients with HBV-ACLF has improved in the past decade.
|
|
|
|
|
|
|
|
|
2021, Vol. 20 
